Chronic Obstructive Pulmonary Disease (COPD), Endothelial Dysfunction, Inflammatory Disease
Conditions
Keywords
chronic obstructive pulmonary disease, acute exacerbation, endothelial dysfunction, flow mediated dilation, systemic inflammation
Brief summary
The purpose of the study is to determine a possible association between the clinical entity of exacerbation, markers of systemic inflammation and endothelial dysfunction in patients with COPD.
Detailed description
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the lungs; however, there is cumulating data suggesting that the inflammatory reaction associated with COPD is not restricted to the lungs but has systemic effects. Patients with COPD have increased cardiovascular morbidity and mortality. The suspected link between increased cardiovascular mortality and systemic inflammation is endothelial dysfunction, which in turn is caused by impaired activity of NO. Endothelial dysfunction has been demonstrated in patients with COPD. Furthermore there is a close correlation between endothelial dysfunction in coronary and peripheral vessels, which allows assessing flow-mediated dilation (FMD) in the brachial artery via high resolution ultrasound as an early predictor of atherosclerosis. Moreover, systemic inflammatory markers correlate with endothelial dysfunction in patients with stable COPD. Exacerbations of COPD are episodes of worsening symptoms characterized by increased airway and systemic inflammation. If systemic inflammation is a cause of endothelial dysfunction in COPD, endothelial function would be suspected to be further impaired during exacerbation and recover thereafter. The purpose of this study is to determine a possible association between the clinical entity of exacerbation, markers of systemic inflammation and endothelial dysfunction in patients with COPD.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* presence of COPD according to standard criteria * acute exacerbation of COPD according to recommended international criteria * over 40 years of age * history of at least 10 py
Exclusion criteria
* pneumonia * history or signs of congestive heart failure, * acute myocardial infarction * thoracotomy incl. resection of lungtissue * interstitial lung disease * acute or chronic renal failure * active malignancy * autoimmune disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of endothelial dysfunction (impaired vasomotor reactivity due to shaer stress) confirmed by non-invasive measurement of flow mediated dilation (FMD) 6-8 weeks after acute exacerbation of COPD | Baseline, Week 6-8 |
Secondary
| Measure | Time frame |
|---|---|
| change of systemic inflammation 6-8 weeks after COPD-exacerbation confirmed by inflammatory markers such as interleukin-6 (IL-6), fibrinogen levels, and C-reactive protein (CRP) levels | baseline, week 6-8 |
Countries
Austria